-
AASLD Exclusive Interview | Dr.Mark Yarchoan: Progress in the Treatment of Intermediate and Advanced HCC, Highlighting the Value of Systemic Therapy
Editor’s Note: At the recently concluded international annual flagship event in the field of hepatology – the American Association for the Study of Liver Diseases Annual Meeting (AASLD 2023), Professor…
-
Dr. Ting Niu: Population-based study reveals prognostic factors and clinical characteristics of gray zone lymphoma patients
From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) annual conference was held grandly in Frankfurt, Germany. The EHA conferences have always been spectacular, with research on lymphoma consistently attracting significant attention. A study on gray zone lymphoma by Dr Ting Niu’s team from West China Hospital of Sichuan University ( Abstract…
-
Dr. Xiaofan Zhu’s Four Study of Rare and Refractory Pediatric Hematologic Diseases at 2023 EHA
The 28th European Hematology Association (EHA) Annual Congress was held in Frankfurt, Germany, from June 8 to 11, 2023. Dr Xiaofan Zhu and his team from the Children’s Hematology Center at the Chinese Academy of Medical Sciences and Peking Union Medical College presented four abstracts at this EHA congress. These abstracts covered various aspects of…
-
Dr. Huiqiang Huang: Just around the corner! Extranodal NK/T-cell lymphoma is ushering in the era of immunotherapy.
Extranodal NK/T-cell lymphoma (ENKTCL) of nasal type is a rare subtype, commonly found in the Asian population and associated with the Epstein-Barr Virus (EBV). At present, the prognosis for patients remains poor, especially for relapsed/refractory (R/R) cases. From June 8 to 11, 2023, the 28th European Hematology Association (EHA) annual meeting was held in Frankfurt,…
-
Bispecific Antibodies Bring New Progress in Follicular Lymphoma Treatment, New CD79b ADC Drugs Show Significant Value in DLBCL Treatment!
The annual European Hematology Association (EHA) conference was recently held in Frankfurt, Germany, in a hybrid online and offline format. As the largest international conference in the European hematology field, the EHA meeting covered a wide range of scientific topics, clinical and basic research, including benign and malignant hematology, discussing the latest developments in the…
-
Dr. Peihua Lu: Targeting CD7 CAR-T Cells Holds Promise for Treating Central Nervous System T-Cell Lymphoblastic Lymphoma/Leukemia
T-cell lymphoblastic lymphoma (T-LBL) is a highly malignant and rare lymphoma with aggressive behavior. It primarily affects adolescents, often presenting with mediastinal lymph node enlargement and commonly accompanied by pericardial and pleural effusions. In some cases, the disease can involve the central nervous system (CNS) with neurological manifestations. About 20% of patients progress to acute…
-
Dr. Jun Ma: On the immunotherapeutic progress and future trends for acute lymphoblastic leukemia based on the studies at EHA 2023
The 28th European Hematology Association (EHA) meeting was held in Frankfurt, Germany from June 8 to June 11, 2023, adopting a hybrid online and offline conference format. As the largest international conference in the European hematology field, the EHA meeting shares topics in various scientific, clinical, and fundamental researches, covering both benign and malignant hematology…
-
Interview with Dr. Andreas Rimner: The Role of Radiotherapy in the Treatment of Stage III Thymoma
Thymoma is one of the most common primary tumors in the anterior mediastinum, representing a group of diseases originating from different thymic epithelial cells, characterized by unique clinical and pathological features, often accompanied by various paraneoplastic syndromes. During the “Multidisciplinary Oncology Committee” session held at the 2023 European Lung Cancer Congress (ELCC), several experts discussed…
Connecting Medical Expertise through Media